Matches in SemOpenAlex for { <https://semopenalex.org/work/W175542906> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W175542906 endingPage "9" @default.
- W175542906 startingPage "224" @default.
- W175542906 abstract "This study evaluated the feasibility, when given in the community, of dose-dense, sequential ATC (doxorubicin, paclitaxel, cyclophosphamide) as adjuvant therapy for breast cancer with four or more metastatic axillary lymph nodes.Patients were recruited after definitive breast cancer surgery if four or more axillary nodes were involved by metastatic cancer and if distant metastases were not present on computed tomographic scan or bone scan. Forty patients received doxorubicin, 90 mg/m2 every 14 days for three cycles; paclitaxel, 250 mg/m2 every 14 days for three cycles; and cyclophosphamide, 3 g/m2 every 14 days for three cycles with filgrastim support. Chemotherapy was administered by the referring physician.Mean dose intensity was 99% for doxorubicin, 96% for paclitaxel, and 99% for cyclophosphamide. Grade 3 toxicities included mucositis (13%), nausea/vomiting (10%), neuropathy (13%), and myalgia/arthralgia (10%). Thirteen patients had neutropenic fever. One patient developed acute leukemia. Three relapses have occurred. Ninety percent of patients are alive and disease-free at a median follow-up of 24 months.ATC can be administered in the community at full doses with acceptable toxicity. Preliminary efficacy data suggest that this high-dose, intensively scheduled regimen warrants comparison with standard therapy for high-risk patients." @default.
- W175542906 created "2016-06-24" @default.
- W175542906 creator A5002568187 @default.
- W175542906 creator A5009898815 @default.
- W175542906 creator A5013802804 @default.
- W175542906 creator A5021961316 @default.
- W175542906 creator A5023000705 @default.
- W175542906 creator A5065608952 @default.
- W175542906 creator A5069099870 @default.
- W175542906 creator A5072682444 @default.
- W175542906 creator A5074009664 @default.
- W175542906 creator A5079371629 @default.
- W175542906 creator A5085708110 @default.
- W175542906 creator A5085775520 @default.
- W175542906 date "1999-08-10" @default.
- W175542906 modified "2023-09-27" @default.
- W175542906 title "Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting." @default.
- W175542906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10439168" @default.
- W175542906 hasPublicationYear "1999" @default.
- W175542906 type Work @default.
- W175542906 sameAs 175542906 @default.
- W175542906 citedByCount "0" @default.
- W175542906 crossrefType "journal-article" @default.
- W175542906 hasAuthorship W175542906A5002568187 @default.
- W175542906 hasAuthorship W175542906A5009898815 @default.
- W175542906 hasAuthorship W175542906A5013802804 @default.
- W175542906 hasAuthorship W175542906A5021961316 @default.
- W175542906 hasAuthorship W175542906A5023000705 @default.
- W175542906 hasAuthorship W175542906A5065608952 @default.
- W175542906 hasAuthorship W175542906A5069099870 @default.
- W175542906 hasAuthorship W175542906A5072682444 @default.
- W175542906 hasAuthorship W175542906A5074009664 @default.
- W175542906 hasAuthorship W175542906A5079371629 @default.
- W175542906 hasAuthorship W175542906A5085708110 @default.
- W175542906 hasAuthorship W175542906A5085775520 @default.
- W175542906 hasConcept C121608353 @default.
- W175542906 hasConcept C126322002 @default.
- W175542906 hasConcept C141071460 @default.
- W175542906 hasConcept C143998085 @default.
- W175542906 hasConcept C2775930923 @default.
- W175542906 hasConcept C2776694085 @default.
- W175542906 hasConcept C2776755627 @default.
- W175542906 hasConcept C2777063308 @default.
- W175542906 hasConcept C2778496288 @default.
- W175542906 hasConcept C2779171977 @default.
- W175542906 hasConcept C2780580376 @default.
- W175542906 hasConcept C2781413609 @default.
- W175542906 hasConcept C530470458 @default.
- W175542906 hasConcept C71924100 @default.
- W175542906 hasConceptScore W175542906C121608353 @default.
- W175542906 hasConceptScore W175542906C126322002 @default.
- W175542906 hasConceptScore W175542906C141071460 @default.
- W175542906 hasConceptScore W175542906C143998085 @default.
- W175542906 hasConceptScore W175542906C2775930923 @default.
- W175542906 hasConceptScore W175542906C2776694085 @default.
- W175542906 hasConceptScore W175542906C2776755627 @default.
- W175542906 hasConceptScore W175542906C2777063308 @default.
- W175542906 hasConceptScore W175542906C2778496288 @default.
- W175542906 hasConceptScore W175542906C2779171977 @default.
- W175542906 hasConceptScore W175542906C2780580376 @default.
- W175542906 hasConceptScore W175542906C2781413609 @default.
- W175542906 hasConceptScore W175542906C530470458 @default.
- W175542906 hasConceptScore W175542906C71924100 @default.
- W175542906 hasIssue "4" @default.
- W175542906 hasLocation W1755429061 @default.
- W175542906 hasOpenAccess W175542906 @default.
- W175542906 hasPrimaryLocation W1755429061 @default.
- W175542906 hasRelatedWork W1980754327 @default.
- W175542906 hasRelatedWork W1983757018 @default.
- W175542906 hasRelatedWork W2004158172 @default.
- W175542906 hasRelatedWork W2007779610 @default.
- W175542906 hasRelatedWork W2018149194 @default.
- W175542906 hasRelatedWork W2038506779 @default.
- W175542906 hasRelatedWork W2387479537 @default.
- W175542906 hasRelatedWork W2795180021 @default.
- W175542906 hasRelatedWork W2801197115 @default.
- W175542906 hasRelatedWork W332553486 @default.
- W175542906 hasVolume "5" @default.
- W175542906 isParatext "false" @default.
- W175542906 isRetracted "false" @default.
- W175542906 magId "175542906" @default.
- W175542906 workType "article" @default.